Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Vir Biotechnology (NASDAQ:VIR) has been analyzed by 5 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $64.8, up 22.26% from the previous $53.00, with a high estimate of $110.00 and a low of $9.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets. The company faces revenue challenges with a -55.93% decline over 3 months but has strong net margin and ROE figures, indicating effective cost management and use of equity.
March 15, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vir Biotechnology has a mixed sentiment from analysts, with an updated average 12-month price target of $64.8. Despite facing revenue challenges, the company's strong net margin and ROE indicate effective management and financial health.
The increase in the average price target suggests a positive outlook from analysts, despite recent revenue challenges. The strong net margin and ROE figures indicate that the company is managing its costs effectively and utilizing its equity capital efficiently, which could attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100